Form 8K Current Report
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): September 29, 2006
SIGA
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-23047
|
13-3864870
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
file number)
|
(I.R.S.
employer
identification
no.)
|
|
420
Lexington Avenue, Suite 408
New
York, New York
(Address
of principal executive offices)
|
|
10170
(Zip
code)
|
Registrant’s
telephone number, including area code: (212) 672-9100
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
r
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r
Soliciting
material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
1.01. Entry
Into a Material Definitive Agreement.
On
September 29, 2006, SIGA Technologies, Inc., a Delaware corporation (“SIGA”)
received a 3 year, $16.5 million contract from the National Institute of Allergy
and Infectious Diseases (“NIAID”) of the National Institutes for Health (“NIH”),
to advance the development of SIGA-246, the company’s smallpox drug candidate.
The award will support the development of SIGA-246 through the preparation
and
filing of a New Drug Application with the Food and Drug
Administration.
On
October 4, 2006, SIGA issued a press release announcing that it had entered
into
the agreement with NIAID. A copy of the press release is attached hereto as
Exhibit 99.1.
Item
1.02. Termination
of a Material Definitive Agreement.
On
October 4, 2006, SIGA, along with its wholly-owned subsidiary SIGA Acquisition
Corp. (“SAC”), exercised their right, pursuant to Section 12.1(a) of that
certain Agreement and Plan of Merger, dated as of June 8, 2006, by and among
SIGA, SAC and PharmAthene, Inc. (the “Merger Agreement”), to terminate the
Merger Agreement because the Closing (as defined in the Merger Agreement) did
not occur on or prior to September 30, 2006. A copy of the Merger Agreement
is
publicly available as an exhibit to SIGA’s Form 8-K filed on June 18,
2006.
On
October 4, 2006, SIGA issued a press release announcing the termination of
the
Merger Agreement. A copy of the press release is attached hereto as Exhibit
99.2.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release dated October 4, 2006.
|
|
99.2
|
Press
Release dated October 4, 2006.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
SIGA
TECHNOLOGIES,
INC.
By:
/s/
Thomas N.
Konatich
Name:
Thomas
N.
Konatich
Title:
Acting
Chief Executive Officer & Chief Financial Officer
Date: October
4, 2006